Posttransplantation care: Role of the primary care physician versus transplant center

Liver Transplantation

Volumn 7, Issue 11 SUPPL. 1, 2001, Pages s2-s12

  McCashland, Timothy M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; GOUT; HEADACHE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION PREVENTION; KIDNEY FAILURE; LIVER TRANSPLANTATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD; MEDICAL SPECIALIST; OBESITY; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; PREGNANCY; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; VACCINATION;

EID: 0038967789     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.28513     Document Type: Article

References (83)

1. Post-transplant care/medical complications
2. Postoperative care: Long-term
3. Long-term issues in liver transplantation
4. Postoperative care after liver transplantation
5. Long-term follow-up of the orthotopic liver transplantation patient
6. Long-term management of the liver transplant recipient
7. Common medical diseases after liver transplantation
8. Long-term medical complications in patients surviving ≥5 years after liver transplant
9. Guidelines for the cancer-related checkup: An update
10. Detection and surveillance of colorectal cancer
11. Recommendations on frequency of Pap test screening
12. Screening for prostate cancer with prostate-specific antigen: An examination of the evidence
13. Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance
14. Screening for thyroid disease in a primary care unit with a thyroid-stimulating hormone assay with a low detection limit
15. Post-transplantation de novo tumors in liver allograft recipients
16. Excessive weight gain after liver transplantation
17. Hyperlipidemia and obesity after orthotopic liver transplantation
18. From malnutrition to obesity: Changes in nutritional status associated with liver transplantation
19. Nutritional care of the chronic post-transplant patient
20. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults
21. Hyperuricaemia after liver transplantation [abstract]
22. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation
23. Solid organ transplantation: Are there predictors for posttransplant noncompliance? A literature overview
24. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease
25. Redefining expectations in transplantation: Management of cardiovascular risk
26. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation
27. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
28. De-novo hypertension after liver transplantation
29. Hypertension after liver transplantation
30. Management strategies for posttransplant hypertension
31. Hypertension in the transplanted patient
32. Nicardipine as antihypertensive therapy in liver transplant recipients: Results of long-term use
33. Metabolic problems in recipients of liver transplants
34. Hyperlipidemia and obesity after liver transplantation
35. Posttransplant medical complications
36. The role of lipid lowering in transplantation
37. Effects of pravastatin on outcomes after cardiac transplantation
38. Impact and management of posttransplant diabetes mellitus
39. Post-transplant diabetes mellitus: The role of immunosuppression
40. Increased cancer risk after liver transplantation: A population-based study
41. Liver transplant recipients are not at increased risk for non-lymphoid solid organ tumors
42. De novo tumours after liver transplantation in adults. What is the actual risk?
43. Posttransplantation de novo tumors in liver allograft recipients
44. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data
45. Liver transplantation for sclerosing cholangitis
46. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation
47. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation
48. Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation
49. Bone disease after liver transplantation
50. Bone mineral density in the long term after liver transplantation
51. Long-term persistence of low bone density in orthotopic liver transplantation
52. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation
53. Predicting bone loss following orthotopic liver transplantation
54. 3
55. Calcitriol in prevention and therapy of osteoporosis after liver transplantation
56. Calcitonin and biphosphonates treatment in bone loss after liver transplantation
57. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alpha calcidol
58. Recovery of menstruation and pregnancy after liver transplantation
59. Pregnancy in liver transplant recipients: Course and outcome in 19 cases
60. Liver transplantation and pregnancy
61. Obstetrical and neonatal outcome in pregnancies after liver transplantation
62. Pregnancy after liver transplantation
63. The immunogenicity of influenza virus vaccine in solid organ transplant recipients
64. Influenza vaccination in liver transplant recipients
65. Efficacy of influenza vaccination in adult liver transplant recipients
66. Influenza infection in patients before and after liver transplantation
67. Hepatitis A antibodies in liver transplant recipients: Evidence for loss of immunity posttransplantation
68. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients
69. Liver transplantation in European patients with the hepatitis B surface antigen
70. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immunoglobulin
71. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
72. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
73. HBV vaccination and liver transplantation for hepatitis B: Winning by recruiting from within?
74. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review
75. Pneumococcal vaccine response in cirrhosis and liver transplantation
76. Infections in liver transplant recipients
77. Neurological complications following liver transplantation
78. Late mortality and morbidity after liver transplantation
79. Causes of late graft loss after liver transplantation
80. Weaning of immunosuppression in long-term liver transplant recipients
81. An analysis of late deaths after liver transplantation